Market Update (NYSE:PFE): Pfizer Announces FDA Acceptance of IBRANCE® (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer

[Business Wire] – Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for filing and granted Priority Review for a supplemental New Drug Application for Pfizer’s breast cancer medication, . . . → Read More: Market Update (NYSE:PFE): Pfizer Announces FDA Acceptance of IBRANCE® (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer Similar Articles: Company Update (NYSE:BMY): U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Advanced Renal Cell Carcinoma Market Update (NYSE:PFE): Pfizer Partners with Breast Cancer Leaders to Chronicle the Lives of Women with Metastatic Breast Cancer through the Lenses of Prominent Photographers Company Update (NYSE:MRK): FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review